Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 31
Filter
1.
J Control Release ; 278: 110-121, 2018 05 28.
Article in English | MEDLINE | ID: mdl-29630987

ABSTRACT

Clinical trials with direct administration of synthetic mRNAs encoding tumor antigens demonstrated safety and induction of tumor-specific immune responses. Their proper delivery to dendritic cells (DCs) requires their protection against RNase degradation and more specificity for dose reduction. Lipid-Polymer-RNA lipopolyplexes (LPR) are attractive mRNA delivery systems and their equipment with mannose containing glycolipid, specific of endocytic receptors present on the membrane of DCs is a valuable strategy. In this present work, we evaluated the capacity of LPR functionalized with a tri-antenna of α-d-mannopyranoside (triMN-LPR) concerning (i) their binding to CD209/DC-SIGN and CD207/Langerin expressing cell lines, human and mouse DCs and other hematopoietic cell populations, (ii) the nature of induced immune response after in vivo immunization and (iii) their therapeutic anti-cancer vaccine efficiency. We demonstrated that triMN-LPR provided high induction of a local inflammatory response two days after intradermal injection to C57BL/6 mice, followed by the recruitment and activation of DCs in the corresponding draining lymph nodes. This was associated with skin production of CCR7 and CXCR4 at vaccination sites driving DC migration. High number of E7-specific T cells was detected after E7-encoded mRNA triMN-LPR vaccination. When evaluated in three therapeutic pre-clinical murine tumor models such as E7-expressing TC1 cells, OVA-expressing EG7 cells and MART-1-expressing B16F0 cells, triMN-LPR carrying mRNA encoding the respective antigens significantly exert curative responses in mice vaccinated seven days after initial tumor inoculation. These results provide evidence that triMN-LPR give rise to an efficient stimulatory immune response allowing for therapeutic anti-cancer vaccination in mice. This mRNA formulation should be considered for anti-cancer vaccination in Humans.


Subject(s)
Cancer Vaccines/administration & dosage , Dendritic Cells/immunology , Neoplasms/therapy , RNA, Messenger/administration & dosage , Animals , Antigens, Neoplasm/immunology , Cancer Vaccines/immunology , Cell Line, Tumor , Cell Movement/immunology , Female , Humans , Injections, Intradermal , Lipids/chemistry , Lymph Nodes/immunology , Mannose/chemistry , Melanoma, Experimental/immunology , Melanoma, Experimental/therapy , Mice , Mice, Inbred C57BL , Neoplasms/immunology , Ovalbumin/immunology , Vaccination
2.
Gene Ther ; 23(2): 144-50, 2016 Feb.
Article in English | MEDLINE | ID: mdl-26488891

ABSTRACT

Targeting viral entry is the most likely gene therapy strategy to succeed in protecting the immune system from pathogenic HIV-1 infection. Here, we evaluated the efficacy of a gene transfer lentiviral vector expressing a combination of viral entry inhibitors, the C46 peptide (an inhibitor of viral fusion) and the P2-CCL5 intrakine (a modulator of CCR5 expression), to prevent CD4⁺ T-cell infection in vivo. For this, we used two different models of HIV-1-infected mice, one in which ex vivo genetically modified human T cells were grafted into immunodeficient NOD.SCID.γc⁻/⁻mice before infection and one in which genetically modified T cells were derived from CD34⁺ hematopoietic progenitors grafted few days after birth. Expression of the transgenes conferred a major selective advantage to genetically modified CD4⁺ T cells, the frequency of which could increase from 10 to 90% in the blood following HIV-1 infection. Moreover, these cells resisted HIV-1-induced depletion, contrary to non-modified cells that were depleted in the same mice. Finally, we report lower normalized viral loads in mice having received genetically modified progenitors. Altogether, our study documents that targeting viral entry in vivo is a promising avenue for the future of HIV-1 gene therapy in humans.


Subject(s)
CD4-Positive T-Lymphocytes/virology , Chemokine CCL5/genetics , Gene Transfer Techniques , HIV Infections/prevention & control , HIV-1 , Recombinant Fusion Proteins/genetics , Virus Internalization , Animals , Antigens, CD34 , CCR5 Receptor Antagonists/therapeutic use , CD4-Positive T-Lymphocytes/immunology , CD4-Positive T-Lymphocytes/transplantation , Female , Genetic Vectors , Humans , Lentivirus/genetics , Mice , Mice, Inbred NOD , Mice, SCID , Receptors, CCR5/metabolism
3.
Scand J Immunol ; 81(4): 229-39, 2015 Apr.
Article in English | MEDLINE | ID: mdl-25683871

ABSTRACT

Foxp3 plays a critical role in the development and function of regulatory T cells (Tregs). Differences in translational and post-translational processing of murine and human Foxp3 have been recently reported. Human Foxp3 exists as four isoforms generated by alternative splicing. Mouse Foxp3 only exists as one isoform, but can be proteolytically cleaved by N-terminal and/or C-terminal proprotein convertase subtilisin/kexins (PCSKs). Here, we show by transcriptome analysis that the proprotein convertases PCSK7, PCSK5 and Furin are present in human CD4(+) T cells with different expression patterns. Notably, after in vitro activation, only PCSK7 and Furin are expressed in Tregs and T effector cells (Teffs), with overexpression of PCSK7 in Tregs compared to Teffs. Human Foxp3 protein displays specific motifs that can be potentially cleaved by convertases. Consequently, we transduced human CD4(+) cells with Foxp3-expressing lentiviral vectors and assessed the generation of proteolytically cleaved Foxp3 forms by Western blot. Three different Foxp3 forms were detected, indicating that human Foxp3 can also be subjected to proteolytic cleavage at the N-terminal and C-terminal ends. These results prompted us to assess the suppressive activity associated with each forms. We observed that full length and N-cleaved Foxp3-transduced CD4(+) T cells similarly suppressed the in vitro proliferation of Teffs. However, the C-cleaved or N&C-cleaved Foxp3 forms afforded almost no suppressive function, indicating a crucial role of the human Foxp3 C-terminal region in Tregs suppressive activity, in marked contrast with the report of a superior suppressive activity for the C-cleaved murine Foxp3 compared to the full length.


Subject(s)
CD4-Positive T-Lymphocytes/immunology , Forkhead Transcription Factors/immunology , Proprotein Convertases/immunology , Subtilisins/immunology , T-Lymphocytes, Regulatory/immunology , Adult , Cell Proliferation , Flow Cytometry , Gene Expression Profiling , Humans , Middle Aged , Protein Isoforms/immunology , Transfection , Young Adult
4.
Blood Cancer J ; 2: e88, 2012 Sep 07.
Article in English | MEDLINE | ID: mdl-22961060

ABSTRACT

Waldenström's macroglobulinemia (WM) is a clonal B-cell lymphoproliferative disorder (LPD) of post-germinal center nature. Despite the fact that the precise molecular pathway(s) leading to WM remain(s) to be elucidated, a hallmark of the disease is the absence of the immunoglobulin heavy chain class switch recombination. Using two-dimensional gel electrophoresis, we compared proteomic profiles of WM cells with that of other LPDs. We were able to demonstrate that WM constitutes a unique proteomic entity as compared with chronic lymphocytic leukemia and marginal zone lymphoma. Statistical comparisons of protein expression levels revealed that a few proteins are distinctly expressed in WM in comparison with other LPDs. In particular we observed a major downregulation of the double strand repair protein Ku70 (XRCC6); confirmed at both the protein and RNA levels in an independent cohort of patients. Hence, we define a distinctive proteomic profile for WM where the downregulation of Ku70-a component of the non homologous end-joining pathway-might be relevant in disease pathophysiology.

5.
Hum Gene Ther ; 10(2): 175-87, 1999 Jan 20.
Article in English | MEDLINE | ID: mdl-10022543

ABSTRACT

Dendritic cells (DCs), the most potent antigen-presenting cells, can be generated from CD34+ hematopoietic stem cells and used for generating therapeutic immune responses. To develop immunotherapy protocols based on genetically modified DCs, we have investigated the conditions for high-level transduction of a large amount of CD34+-derived DCs. Thus, we have used an efficient and clinically applicable protocol for the retroviral transduction of cord blood (CB) or mobilized peripheral blood (MPB) CD34+ cells based on infection with gibbon ape leukemia virus (GALV)-pseudotyped retroviral vectors carrying the nls-LacZ reporter gene. Infected cells have been subsequently cultured under conditions allowing their dendritic differentiation. The results show that using a growth factor combination including granulocyte-macrophage colony-stimulating factor plus tumor necrosis factor alpha plus interleukin 4 plus stem cell factor plus Flt3 ligand, more than 70% of DCs derived from CB or MPB CD34+ cells can be transduced. Semiquantitative PCR indicates that at least two proviral copies per cell were detected. Transduced DCs retain normal immunophenotype and potent T cell stimulatory capacity. Finally, by using a semisolid methylcellulose assay for dendritic progenitors (CFU-DCs), we show that more than 90% of CFU-DCs can be transduced. Such a highly efficient retrovirus-mediated gene transfer into CD34+-derived DCs makes it possible to envision the use of this methodology in clinical trials.


Subject(s)
Antigens, CD34/immunology , Dendritic Cells/metabolism , Fetal Blood/cytology , Gene Transfer Techniques , Retroviridae/genetics , Base Sequence , Cell Division , Cell Line , DNA Primers , Dendritic Cells/immunology , Hematopoietic Stem Cell Mobilization , Humans , Immunophenotyping , T-Lymphocytes/cytology , Transduction, Genetic
6.
Hum Gene Ther ; 9(2): 225-34, 1998 Jan 20.
Article in English | MEDLINE | ID: mdl-9472782

ABSTRACT

The best methods for transducing hematopoietic progenitor cells usually involve either direct co-cultivation with virus-producing cells or human stromal supportive cells. However, these methods cannot be safely or easily applied to clinical use. Therefore, we aimed at improving retrovirus-mediated gene transfer into hematopoietic progenitors derived from cord blood CD34+ cells using viral supernatant to levels achieved at least with direct co-cultivation and under conditions that are suitable for clinical applications. In a first set of experiments, CD34+ cells were infected with supernatant containing amphotropic retroviral particles carrying the nls-lacZ reporter gene and the effects of centrifugation, cell adhesion to fibronectin, and Polybrene on the transduction of both clonogenic progenitors (CFC) and long-term culture initiating cells (LTC-IC) were studied. Transduction efficiency was evaluated on the percentage and total number of progenitors expressing the beta-galactosidase activity. Results show that a 48-hr infection of CD34+ cells with viral supernatant combining centrifugation at 1000 x g for 3 hr followed by adhesion to fibronectin allows transduction levels for both CFC and LTC-IC to be reached that are as good as using direct co-cultivation. In a second set of experiments, CD34+ cells were infected using this optimized protocol with pseudotyped retroviral particles carrying the gibbon ape leukemia virus (GALV) envelope protein. Under these conditions, between 50 and 100% of CFC and LTC-IC were transduced. Thus, we have developed a protocol capable of highly transducing cord blood progenitors under conditions suitable for a therapeutical use.


Subject(s)
Fetal Blood/virology , Gene Transfer Techniques , Genetic Vectors/therapeutic use , Leukemia Virus, Gibbon Ape/genetics , Stem Cells/virology , Antigens, CD34/analysis , Cell Line , Centrifugation , Coculture Techniques , Culture Media , Fetal Blood/cytology , Fetal Blood/drug effects , Fibronectins/pharmacology , Hexadimethrine Bromide/pharmacology , Humans , Leukemia Virus, Gibbon Ape/growth & development , Stem Cells/drug effects , Stem Cells/metabolism
7.
Stem Cells ; 15(3): 214-22, 1997.
Article in English | MEDLINE | ID: mdl-9170213

ABSTRACT

The cycling status of cord blood progenitors and the culture conditions triggering their activation into S-phase have been studied using flow cytometry and a 3H-thymidine suicide assay. Mononuclear cells cultured either in Iscove's modified Dulbecco's medium (IMDM) +/- 10% fetal calf serum ([FCS]; IMDM + FCS) or in Dulbecco's modified Eagle's medium (DMEM) +/- 10% newborn bovine serum ([NBS]; DMEM + NBS) were stimulated by various growth factors (GFs). Results showed that CD34+ cells, clonogenic progenitors (colony forming cells [CFCs]) and long-term culture initiating cells (LTC-IC) present in freshly harvested cord blood were quiescent. CFC numbers were maintained without cycling after 48-h cultures in serum-containing media without GFs. Addition of interleukin 3 (IL-3) + IL-6 + stem cell factor stimulated into S-phase approximately 40% of CFCs within 24-48 h, without modifying their number except in DMEM + NBS where erythroid progenitors decreased. When cells were stimulated in IMDM + FCS by these three GFs + insulin-like growth factor I and basic fibroblast growth factor used at high concentration, more than 50% of CFCs were in S-phase and their total number was maintained. The latter culture conditions also recruited up to 66% of LTC-IC into S-phase. Our data underline the importance of the combination of GFs and culture media used for optimizing the cycling and maintenance of CFCs and LTC-IC within two days.


Subject(s)
Fetal Blood/cytology , Growth Hormone/pharmacology , Hematopoietic Stem Cells/cytology , Hematopoietic Stem Cells/drug effects , Antigens, CD34/analysis , Blood Proteins/pharmacology , Cell Culture Techniques/methods , Cell Cycle/drug effects , Cells, Cultured , Female , Growth Substances/pharmacology , Hematopoietic Stem Cells/chemistry , Humans , S Phase/drug effects
8.
Leuk Lymphoma ; 27(5-6): 487-94, 1997 Nov.
Article in English | MEDLINE | ID: mdl-9477130

ABSTRACT

We have compared the effects of AcSDKP, Thymosin beta4 (Tbeta4), MIP1alpha and TGFbeta on acute myeloid leukemia (AML) and B-lineage acute lymphoid leukemia (B-ALL) cells using liquid cultures in the presence of GM-CSF, IL-3 and SCF for AML cells and IL-3 and IL-7 for ALL cells. Each molecule was added daily and cell proliferation was evaluated on day 3 by thymidine incorporation. Whereas TGFbeta was found inhibitory in all the AML and B-ALL cases studied, MIP1alpha was inhibitory in 6/12 AML cases and had no effect on B-ALL cells. AcSDKP and Tbeta4 showed an inhibitory effect in a few cases but only at high doses which were inactive on normal cells. Thus, our study not only confirms the effect of TGFbeta, MIP1alpha and AcSDKP on AML cells but also provides new data concerning their effect on B-ALL and the possible inhibitory effect of AcSDKP at high doses. Furthermore, we show for the first time the effect of Tbeta4 on leukemic cells. Altogether, our data indicate differences of sensitivity of leukemic cells to negative regulators, some leukemias being inhibited by one or several of these molecules whereas others were unresponsive to all used. The clinical relevance of these observations still remains to be determined.


Subject(s)
Burkitt Lymphoma/pathology , Cell Division/drug effects , Leukemia, Myeloid, Acute/pathology , Macrophage Inflammatory Proteins/pharmacology , Oligopeptides/pharmacology , Thymosin/pharmacology , Transforming Growth Factor beta/pharmacology , Adolescent , Adult , Aged , Chemokine CCL4 , Child , Child, Preschool , Female , Humans , Infant , Male , Middle Aged , Tumor Cells, Cultured/drug effects
9.
Blood ; 88(4): 1277-83, 1996 Aug 15.
Article in English | MEDLINE | ID: mdl-8695845

ABSTRACT

We successfully infected fluorescence-activated cell-sorted CD34+ cells from normal cord blood by the human cytomegalovirus (HCMV) laboratory strain Towne. An inhibitory effect of HCMV on clonogenic myeloid progenitors was observed in primary methylcellulose cultures. After an initial 7-day liquid culture of CD34(+)-infected cells, this inhibition was further amplified in secondary methylcellulose cultures, then involving both the myeloid and erythroid lineages. Under these conditions, viral DNA was detected both in erythroid and myeloid colonies using the polymerase chain reaction (PCR), but reverse transcription PCR (RT-PCR) failed to detect viral RNA. In contrast, when CD34(+)-infected cells were maintained in liquid suspension, both immediate, early, and late transcripts were detected as soon as day 3. In addition, viral production was demonstrated in the culture supernatants, thus confirming that a complete viral cycle occurred under liquid conditions. Furthermore, by resorting cells into CD34+ and CD34- fractions, we showed by RT-PCR that viral replication took place in cells still expressing CD34 antigen, whereas no RNA was found in more differentiated cells that had subsequently lost their CD34 antigen. These findings suggest that HCMV replication can occur at the early steps of progenitor differentiation and may be involved in the viral-induced myelosuppression.


Subject(s)
Cytomegalovirus/pathogenicity , Hematopoiesis , Hematopoietic Stem Cells/microbiology , Antigens, CD34/analysis , Antigens, Viral/analysis , Base Sequence , Cells, Cultured , DNA Primers/chemistry , DNA, Viral/analysis , Fetal Blood , Gene Expression Regulation, Viral , Hematopoietic Stem Cells/cytology , Hematopoietic Stem Cells/immunology , Humans , Molecular Sequence Data , RNA, Messenger/genetics , RNA, Viral/analysis , Virus Replication
10.
Exp Hematol ; 24(7): 776-82, 1996 Jun.
Article in English | MEDLINE | ID: mdl-8647227

ABSTRACT

Thymosin beta4 (Tbeta4), isolated from the calf thymus fraction 5, has a ubiquitous localization and plays a pleiotropic role in both the immune and nonimmune systems. Because it contains at its N-terminal end the sequence of a known inhibitor of hematopoiesis, the acetylated tetrapeptide Ac-N-Ser-Asp-Lys-Pro (AcSDKP, Goralatide), we have assayed Tbeta4 on human hematopoietic cells. We demonstrate that it inhibits normal bone marrow progenitor cell growth; indeed, it decreased the growth of both granulo-macrophagic and erythroid progenitors and reduces their percentage in S phase. Furthermore, we show that Tbeta4 reduces both the clonogenicity and the cell proliferation of purified CD34+ cells induced by a combination of seven growth factors. Although Tbeta4's inhibitory effect is very similar to that of AcSDKP, we demonstrate, using neutralizing antibodies and a truncated form of Tbeta4 devoid of the AcSDKP sequence, that the inhibitory effect of Tbeta4 is not mediated by the sequence AcSDKP. These data indicate that Tbeta4 is a novel inhibitor for human normal hematopoietic progenitors.


Subject(s)
Growth Inhibitors/pharmacology , Hematopoietic Stem Cells/drug effects , Thymosin/pharmacology , Amino Acid Sequence , Animals , Antibodies, Monoclonal/immunology , Antibodies, Monoclonal/pharmacology , Cattle , Cells, Cultured , Colony-Forming Units Assay , Erythroid Precursor Cells/cytology , Erythroid Precursor Cells/drug effects , Hematopoietic Cell Growth Factors/pharmacology , Humans , Molecular Sequence Data , Oligopeptides/antagonists & inhibitors , Oligopeptides/immunology , Oligopeptides/pharmacology , Recombinant Proteins/pharmacology , Thymosin/antagonists & inhibitors , Thymosin/immunology
11.
Leuk Lymphoma ; 21(3-4): 267-80, 1996 Apr.
Article in English | MEDLINE | ID: mdl-8726408

ABSTRACT

The spontaneous proliferation and the effects of 8 various growth factors (GF) were evaluated on leukemic cells from 27 patients with B-lineage ALL. Two groups of ALLs were distinguished. ALLs from group I (21 patients) exhibited a low spontaneous proliferative rate and were stimulated by IL-3 + IL-7 +/- SCF and/or LIF, while ALLs from group II (6 patients) had a high spontaneous proliferative rate and did no longer require this combination of GFs for proliferation. No effect of bFGF, IGF-I, IL-10 and IL-11 alone or in combination, was observed. Such differences in the behaviour of B-ALLs indicated that the GF requirement of ALL blasts was not related to the presence of serum in the culture nor to the pattern of reactivity of ALL blasts for B lymphoid markers or CD34 antigen. Furthermore, we showed in 1/9 cases that high proliferation might be due to an overexpression of the bcl-2 proto-oncogene and to the acquisition of an autocrine secretion.


Subject(s)
Burkitt Lymphoma/metabolism , Burkitt Lymphoma/pathology , Cytokines/pharmacology , Growth Substances/pharmacology , Proto-Oncogene Proteins/biosynthesis , Adult , Apoptosis/drug effects , Cell Division/drug effects , Cell Division/physiology , Cell Survival/drug effects , Child , Child, Preschool , Female , Humans , Infant , Male , Proto-Oncogene Mas , Proto-Oncogene Proteins c-bcl-2 , RNA, Messenger/metabolism
12.
Blood ; 85(8): 2154-61, 1995 Apr 15.
Article in English | MEDLINE | ID: mdl-7536493

ABSTRACT

The hierarchical level of stem cell involvement in acute promyelocytic leukemia (APL) characterized by the pathognomonic PML-RARA fusion gene is unknown. To determine if the cells of the primitive hematopoietic stem cell compartment are involved in the leukemic process, we have used molecular and cell sorting techniques in peripheral blood and bone marrow (BM) cells at diagnosis from three patients with APL and t(15; 17). In two of them, clonality analysis was also possible using the BstXI polymorphic site of the PGK gene. The PML-RARA fusion gene was readily identified by reverse transcriptase-polymerase chain reaction (RT-PCR) analysis of BM cells obtained at diagnosis in all three patients. These same samples were then used to sort CD34+ cells and their CD38+ and CD38- subsets by fluorescence-activated cell sorting. In both female patients, CD34+/CD38+ and CD34+/CD38- cell fractions were polyclonal using PCR, whereas a monoclonal pattern was identified at the BM sample obtained at diagnosis either by Southern blotting or by PCR. Because of the high sensitivity of the PCR analysis, the polyclonal pattern of these cell populations could mask the presence of a minor clone. To detect this clone, we preformed RT-PCR analysis for t(15; 17). In one female patient, the abnormal PML-RAR fusion gene was found only in the more mature CD34+/CD38+ cell fraction using a nested PCR approach, whereas the polyclonal CD34+/CD38- fraction was PML-RARA negative. These findings were confirmed in a third patient with APL in whom the PML-RARA transcripts were absent in the CD34+/CD38- cell fraction. To study the clonality at the level of clonogenic progenitors, we used in one patient PGK analysis by PCR of individual burst-forming units-erythroid and colony-forming units-granulocyte-macrophage obtained from the CD34+/CD38- and CD34+/CD38+ cell populations at diagnosis and from the BM sample obtained during remission. The two highly purified cell populations gave rise to morphologically normal colonies clonal for both the BstXI site containing (A) and the BstXI site lacking (B) PGK allelles, indicating their polyclonal content, a pattern that was also found in clonogenic progenitors obtained at remission. These findings strongly suggest that the primitive hematopoietic stem cells as defined by the CD34+/CD38- antigens are not involved by the neoplastic process in APL. These results may have important implications for autografting strategies of retinoic acid/chemotherapy-resistant or relapsed patients.


Subject(s)
Biomarkers, Tumor/analysis , Bone Marrow/pathology , Clone Cells/chemistry , Hematopoietic Stem Cells/chemistry , Leukemia, Promyelocytic, Acute/pathology , Oncogene Proteins, Fusion/analysis , ADP-ribosyl Cyclase , ADP-ribosyl Cyclase 1 , Adult , Aged , Antigens, CD/analysis , Antigens, CD34 , Antigens, Differentiation/analysis , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Base Sequence , Bone Marrow/chemistry , Colony-Forming Units Assay , Female , Humans , Leukemia, Promyelocytic, Acute/drug therapy , Leukemia, Promyelocytic, Acute/genetics , Male , Membrane Glycoproteins , Middle Aged , Molecular Sequence Data , Neoplastic Stem Cells/chemistry , Phosphoglycerate Kinase/genetics , Polymerase Chain Reaction , Polymorphism, Restriction Fragment Length , Remission Induction , Tumor Stem Cell Assay
13.
J Immunol ; 154(4): 1577-86, 1995 Feb 15.
Article in English | MEDLINE | ID: mdl-7836743

ABSTRACT

v-mpl is a constitutively activated, truncated form of a cytokine receptor that has been transduced in a murine retrovirus, the myeloproliferative leukemia virus (MPLV). Expression of this oncogene results in the factor-independent proliferation of myeloid, erythroid, megakaryocytic, and mast precursor cells, which retain the ability to differentiate. However, no lymphoid disease was ever reported. To determine whether MPLV could infect and transform very early B cells and their precursors (BCPs), lymphoid long-term bone marrow cultures were infected with a helper-free MPLV. Within 3 wk after infection, highly proliferating BCPs could be isolated. These cells were able to clone spontaneously in semi-solid cultures, grown in the absence of feeder cell layer or exogenous growth factor and rapidly produced tumors after s.c. injection into synegic irradiated mice. In addition, MPLV transformation of pre-B cells led to the induction of an autocrine activity. Immunophenotypic and molecular analysis indicated that MPLV transformed early pro-B, pro-B, and pre-B cells, according to the expression of HSA, CD43, B220, Thy1, s-IgM and BP1 Ags, and to the rearrangements of Ig genes. Interestingly, MPLV-transformed BCPs expressed Mac1 Ag without acquiring further characteristics of macrophagic differentiation. Although the v-mpl cytoplasmic domain is devoid of tyrosine kinase consensus sequence, MPLV-transformed pre-B cells contained a major approximately 105-kDa tyrosine-phosphorylated protein that was not detected in uninfected cells or in cells transformed by the Abelson viral oncogene (v-abl). These results demonstrate that, like v-abl, the truncated cytokine receptor v-mpl is able to transform BCPs in vitro and suggest that the oncogenic transformation of BCPs by either v-mpl or v-abl use different pathways.


Subject(s)
B-Lymphocytes/virology , Cell Transformation, Neoplastic/genetics , Cell Transformation, Viral , Hematopoietic Stem Cells/virology , Leukemia Virus, Murine/physiology , Oncogenes , Receptors, Cytokine/physiology , Animals , Antigens, Differentiation/biosynthesis , Base Sequence , Cell Differentiation , Cell Division , Cell Line, Transformed/transplantation , Cells, Cultured , Culture Media, Conditioned , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Molecular Sequence Data , Neoplasm Transplantation , Neoplasms, Experimental , Oncogene Proteins v-abl/physiology , Phosphoproteins/metabolism , Phosphorylation , Protein Processing, Post-Translational , Protein-Tyrosine Kinases/metabolism , Receptors, Cytokine/genetics
14.
Blood ; 84(8): 2506-14, 1994 Oct 15.
Article in English | MEDLINE | ID: mdl-7522632

ABSTRACT

Tumor necrosis factor alpha (TNF alpha), as a modulator of hematopoiesis, interacts with many growth factor receptors, such as interleukin-3, granulocyte-macrophage colony-stimulating factor (CSF), and granulocyte-CSF receptors. Here, we studied the interactions between TNF alpha and the stem cell factor (SCF) receptor, c-kit, in normal CD34+ hematopoietic progenitors and their leukemic counterpart, ie, acute myeloid leukemic (AML) CD34+ cells coexpressing c-kit antigen. The results showed that (1) incubation of normal bone marrow mononuclear cells with 200 U/mL rhTNF alpha for 20 hours induced a diminution of 31.2% +/- 5.2% of CD34+ cells coexpressing c-kit; (2) the same decrease was observed using purified CD34+ cells and, furthermore, their proliferative response to SCF was inhibited by 31.5% +/- 7.3% after exposure to TNF alpha; (3) similar experiments performed on CD34+ c-kit+ AML cells from 11 patients gave comparable results. Further analysis at the mRNA level indicated that TNF alpha decreased c-kit mRNA transcripts. Moreover, using monoclonal antibodies against the two types of TNF alpha receptors, p75 and p55, we showed that the downregulation of c-kit proto-oncogene product by TNF alpha, on normal and leukemic CD34+ cells, was exclusively mediated by the TNF alpha p55 receptor. Therefore, we conclude that TNF alpha acts as a downregulator of the SCF receptor expression.


Subject(s)
Gene Expression Regulation, Neoplastic , Hematopoietic Stem Cells/metabolism , Leukemia, Myeloid, Acute/metabolism , Proto-Oncogene Proteins/genetics , Receptor Protein-Tyrosine Kinases/genetics , Receptors, Colony-Stimulating Factor/genetics , Receptors, Tumor Necrosis Factor/physiology , Tumor Necrosis Factor-alpha/pharmacology , Adult , Aged , Aged, 80 and over , Antigens, CD/analysis , Antigens, CD34 , Base Sequence , Bone Marrow Cells , Cell Division , Hematopoietic Cell Growth Factors/pharmacology , Hematopoietic Stem Cells/cytology , Humans , Leukemia, Myeloid, Acute/pathology , Middle Aged , Molecular Sequence Data , Proto-Oncogene Mas , Proto-Oncogene Proteins c-kit , Stem Cell Factor , Tumor Cells, Cultured
15.
Leuk Lymphoma ; 12(3-4): 307-14, 1994 Jan.
Article in English | MEDLINE | ID: mdl-8167562

ABSTRACT

To determine the efficacy of recombinant human erythropoietin at pharmacological doses in myelodysplastic syndromes (MDS) without excess of blasts, 20 patients with refractory anemias (RA) or refractory anemias with ring sideroblasts (RARS) were treated in an open study with escalating doses from 40 U/kg to 300 U/kg three times a week subcutaneously during a period of 3 months. Maintenance therapy at the lowest effective dose was continued in responders. A dose response of CFU-E and BFU-E to Epo was analysed at the entry. Bone marrow examination with an in vitro study of hematopoietic progenitors was performed before and after the first three months. Seven of 20 patients responded: a total recovery was observed in 3 patients; one became transfusion independent and a reduction of 50% of the transfusion requirement was achieved in 3 others. 3 patients are still receiving treatment for 2, 3 and 4 years. No significant correlation was found between the in vitro and clinical response. A non parametric analysis of responders and non responders emphasised the importance of a long delay between the diagnosis and the treatment, (p = 0.024) and an endogenous Epo level less than 100 mU/ml (p = 0.025) in order to predict the efficacy of rhEpo. This study offers evidence that patients with refractory anemias without excess of blasts in the bone marrow respond to rhEpo at pharmacological doses. Larger studies are required in order to define the patients who may respond and to elucidate the mechanism of the positive effect of rhEpo.


Subject(s)
Anemia/drug therapy , Erythropoietin/therapeutic use , Myelodysplastic Syndromes/blood , Myelodysplastic Syndromes/drug therapy , Adult , Aged , Aged, 80 and over , Anemia/blood , Anemia/etiology , Anemia/pathology , Bone Marrow/pathology , Colony-Forming Units Assay , Female , Hematopoietic Stem Cells/pathology , Humans , Male , Middle Aged , Myelodysplastic Syndromes/pathology , Recombinant Proteins/therapeutic use
16.
Blood ; 82(11): 3307-14, 1993 Dec 01.
Article in English | MEDLINE | ID: mdl-7694679

ABSTRACT

The tetrapeptide Acetyl-N-Ser-Asp-Lys-Pro (AcSDKP, Seraspenide; Ipsen-Biotech, Paris, France), an inhibitor of murine spleen colony-forming units reduces the number and the percentage in DNA synthesis of progenitors from human unfractionated bone marrow. To determine whether AcSDKP may directly affect the growth potential of purified progenitors even at the most primitive level, CD34+HLA-DRhigh and CD34++HLA-DRlow cells were highly purified by cell sorting. Then, CD34+ subsets were stimulated in liquid culture with combinations of growth factors (GFs) and AcSDKP was added for 20 hours or 6 days and cells plated in methylcellulose. After a 20-hour incubation, we show that AcSDKP (at 10(-10) mol/L) significantly inhibits the colony formation of both CD34+ subsets. Moreover, when added daily for 6 days, AcSDKP: (1) reduces the proliferation of both CD34+ cell fractions stimulated by 3 or 7 GFs, and (2) decreases the number of progenitors generated from the CD34+HLA-DRhigh and CD34++HLA-DRlow cell fractions. Furthermore, we show for the first time, using both high proliferative potential cell and long-term culture initiating cell assays, that AcSDKP inhibits the most primitive cells contained in the CD34++HLA-DRlow subpopulation. Finally, by using limiting dilution assays we demonstrated that AcSDKP acts directly at a single cell level and that its inhibitory effect is reversible and dose dependent.


Subject(s)
Antigens, CD/analysis , Growth Substances/pharmacology , Hematopoietic Stem Cells/drug effects , Oligopeptides/pharmacology , Amino Acid Sequence , Antigens, CD34 , Cell Division/drug effects , Cells, Cultured , HLA-DR Antigens/analysis , Hematopoietic Stem Cells/immunology , Humans , Molecular Sequence Data
17.
Blood ; 82(2): 417-29, 1993 Jul 15.
Article in English | MEDLINE | ID: mdl-7687158

ABSTRACT

To study the frontiers between pluripotent stem cells and committed progenitors and to further define the B-cell pathway in adult bone marrow (BM), CD34+ subpopulations and CD34- B-lineage cells were analyzed by multiparameter flow cytometry, studied by light and electron microscopy, and in short-term and long-term cultures (LTC). While the total CD34+ cells represent 4.9% +/- 0.8 of BM mononuclear cells within the lymphoid-blast window, 73.8 +/- 3.5%, 14.4 +/- 1.8% and 8.8 +/- 2.9% of them were CD34+ CD10- CD19-, CD34+ CD10+ CD19+, and CD34+ CD10+ CD19-, respectively. CD34+ CD10+ CD19+ cells represent a smal homogeneous TdT4 c micro-blast population. Although expressing CD38 and high level of HLA-DR antigens, like myeloid committed progenitors, they did not generate LTC, myeloid, and T lymphoid colonies suggesting that the CD34+ CD10+ CD19+ population represents exclusively B lymphoid committed progenitors. By contrast, all myeloid progenitors and LTC-initiating cells were found in the CD34+ CD10- CD19- cell fraction. This fraction appeared more heterogeneous and contained CD38- HLA-DRlow small cells, larger blasts, and promonocyte-like cells exhibiting small peroxidase-positive granules. Interestingly, CD10 was also present on CD34+ CD19- cells. This population mainly coexpressed CD33 and gave rise to macrophagic colonies.


Subject(s)
B-Lymphocyte Subsets , B-Lymphocytes/cytology , Bone Marrow Cells , Hematopoietic Stem Cells/cytology , Adult , Antigens, CD/analysis , Antigens, CD19 , Antigens, CD34 , Antigens, Differentiation, B-Lymphocyte/analysis , B-Lymphocytes/immunology , Cells, Cultured , DNA Nucleotidylexotransferase/analysis , Flow Cytometry , HLA-DR Antigens/analysis , Humans , Immunophenotyping , Microscopy, Electron , Neprilysin/analysis
18.
Nephrol Dial Transplant ; 8(7): 614-20, 1993.
Article in English | MEDLINE | ID: mdl-8396745

ABSTRACT

Eleven uraemic patients were treated with recombinant human erythropoietin (rHuEpo). Seven haemodialysis patients and four peritoneal dialysis patients received a starting dose of 80 IU/kg i.v. and 40 IU/kg s.c. respectively, thrice weekly. The number of burst-forming-unit erythroid (BFU-E), colony-forming-unit erythroid (CFU-E), granulocyte-monocyte (CFU-GM) and megakaryocyte (CFU-Mk) were assayed 2 weeks before (D0), and 1 (M1) and 6 months (M6) after the initiation of rHuEpo treatment by means of a commonly applied in-vitro clonal assay. All the patients showed the same haematopoietic response. A significant increase of CFU-E and CFU-Mk could be observed within 1 month of treatment. At this time, no significant modification was observed in BFU-E and CFU-GM number. At the 6th month the increase of CFU-E was maintained, whereas a significant fall of BFU-E, CFU-GM and CFU-Mk was observed. These results suggest that in-vivo effects of rHuEpo are not restricted to the erythroid lineage but that erythropoietin might also act as a co-factor of megakaryopoiesis. In the long term erythropoietin might induce erythroid differentiation in multipotent progenitor cells at the expense of the non-erythroid progenitors.


Subject(s)
Bone Marrow/drug effects , Erythropoietin/pharmacology , Hematopoietic Stem Cells/drug effects , Adult , Aged , Aged, 80 and over , Bone Marrow Cells , Cells, Cultured , Erythroid Precursor Cells/drug effects , Female , Humans , Male , Middle Aged , Recombinant Proteins/pharmacology
19.
Exp Hematol ; 20(8): 991-7, 1992 Sep.
Article in English | MEDLINE | ID: mdl-1380463

ABSTRACT

Although tumor necrosis factor alpha (TNF alpha) exerts a variety of activities on hematopoietic cells, suggesting it may have some potential therapeutic applications, its long-term effects on hematopoiesis are not well defined. Therefore, we took the advantage of long-term bone marrow cultures (LTBMCs) to evaluate the long-term role of TNF alpha on both the microenvironment and the hematopoietic progenitors. LTBMCs were inoculated with 100 U/ml of recombinant human TNF alpha (rhTNF alpha) either at the onset of the cultures (d0) or at day 21 (d21) when the adherent layer (AL) was already established. Then TNF alpha was added at each weekly medium change. The cellularity and the content of progenitors in both the nonadherent layer (NAL) and AL, the formation of the AL, and the presence of various cytokines in the supernatants were examined weekly. The data showed 1) a strong and durable inhibitory effect on total nonadherent cells; 2) a rapid and transient inhibition of NA progenitors, whereas adherent progenitors were lately affected; and 3) microenvironmental changes consisting of the disappearance of adipocytes and the secretion of high levels of interleukin 6. The results suggest that the inhibitory effects of TNF alpha on the NAL are in part counterbalanced by stromal modifications that in turn lead to a faster exhaustion of hematopoiesis.


Subject(s)
Bone Marrow Cells , Tumor Necrosis Factor-alpha/pharmacology , Bone Marrow/chemistry , Bone Marrow/drug effects , Cell Adhesion/drug effects , Cells, Cultured , Enzyme-Linked Immunosorbent Assay , Granulocyte Colony-Stimulating Factor/analysis , Granulocyte-Macrophage Colony-Stimulating Factor/analysis , Hematopoiesis/drug effects , Hematopoietic Stem Cells/chemistry , Hematopoietic Stem Cells/cytology , Hematopoietic Stem Cells/drug effects , Humans , Interleukin-1/analysis , Interleukin-3/analysis , Interleukin-6/analysis , Recombinant Proteins/pharmacology , Time Factors , Tumor Necrosis Factor-alpha/analysis
SELECTION OF CITATIONS
SEARCH DETAIL
...